Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Short-Term Debt issuances (2024 - 2025)

Cytek Biosciences' Short-Term Debt issuances history spans 2 years, with the latest figure at $1.4 million for Q4 2025.

  • For Q4 2025, Short-Term Debt issuances fell 50.0% year-over-year to $1.4 million; the TTM value through Dec 2025 reached $5.6 million, up 32.86%, while the annual FY2025 figure was $5.6 million, 33.51% up from the prior year.
  • Short-Term Debt issuances reached $1.4 million in Q4 2025 per CTKB's latest filing, down from $2.1 million in the prior quarter.
  • In the past five years, Short-Term Debt issuances ranged from a high of $2.8 million in Q4 2024 to a low of -$3000.0 in Q2 2024.